BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26890003)

  • 1. The Potential Biomarkers to Identify the Development of Steatosis in Hyperuricemia.
    Tan Y; Liu X; Zhou K; He X; Lu C; He B; Niu X; Xiao C; Xu G; Bian Z; Zu X; Zhang G; Zhang W; Lu A
    PLoS One; 2016; 11(2):e0149043. PubMed ID: 26890003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
    Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
    J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults.
    Zheng X; Gong L; Luo R; Chen H; Peng B; Ren W; Wang Y
    Lipids Health Dis; 2017 Oct; 16(1):202. PubMed ID: 29037239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Metabolic Biomarkers to Identify Interstitial Lung Abnormalities.
    Tan Y; Jia D; Lin Z; Guo B; He B; Lu C; Xiao C; Liu Z; Zhao N; Bian Z; Zhang G; Zhang W; Liu X; Lu A
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27438829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: Lesson learnt from tertiary referral center.
    Sandra S; Lesmana CRA; Purnamasari D; Kurniawan J; Gani RA
    Diabetes Metab Syndr; 2019; 13(1):424-428. PubMed ID: 30641737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study.
    Lu ZY; Shao Z; Li YL; Wulasihan M; Chen XH
    World J Gastroenterol; 2016 Apr; 22(13):3663-9. PubMed ID: 27053858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between the hyperuricemia and nonalcoholic fatty liver disease risk in a Chinese population: A retrospective cohort study.
    Yang C; Yang S; Xu W; Zhang J; Fu W; Feng C
    PLoS One; 2017; 12(5):e0177249. PubMed ID: 28510581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver Fat Content Is Associated with Elevated Serum Uric Acid in the Chinese Middle-Aged and Elderly Populations: Shanghai Changfeng Study.
    Lin H; Li Q; Liu X; Ma H; Xia M; Wang D; Li X; Wu J; Zhao N; Pan B; Gao X
    PLoS One; 2015; 10(10):e0140379. PubMed ID: 26473493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomic profiles delineate the effect of Sanmiao wan on hyperuricemia in rats.
    Jiang T; Qian J; Ding J; Wang G; Ding X; Liu S; Chen W
    Biomed Chromatogr; 2017 Feb; 31(2):. PubMed ID: 27450803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice.
    Tu LN; Showalter MR; Cajka T; Fan S; Pillai VV; Fiehn O; Selvaraj V
    Sci Rep; 2017 Jul; 7(1):6120. PubMed ID: 28733574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between non-alcoholic fatty liver with metabolic risk factors and brachial-ankle pulse wave velocity.
    Zhu WH; Fang LZ; Lu CR; Dai HL; Chen JH; Qiao QH; Chen LY
    World J Gastroenterol; 2015 Sep; 21(35):10192-9. PubMed ID: 26401084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    Jaruvongvanich V; Ahuja W; Wirunsawanya K; Wijarnpreecha K; Ungprasert P
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1031-1035. PubMed ID: 28639970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease.
    Dong S; Zhan ZY; Cao HY; Wu C; Bian YQ; Li JY; Cheng GH; Liu P; Sun MY
    World J Gastroenterol; 2017 Apr; 23(15):2771-2784. PubMed ID: 28487615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping of the circulating metabolome reveals α-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease.
    Rodríguez-Gallego E; Guirro M; Riera-Borrull M; Hernández-Aguilera A; Mariné-Casadó R; Fernández-Arroyo S; Beltrán-Debón R; Sabench F; Hernández M; del Castillo D; Menendez JA; Camps J; Ras R; Arola L; Joven J
    Int J Obes (Lond); 2015 Feb; 39(2):279-87. PubMed ID: 24675715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A targeted metabolomic profiling of plasma acylcarnitines in nonalcoholic fatty liver disease.
    Chang Y; Gao XQ; Shen N; He J; Fan X; Chen K; Lin XH; Li HM; Tian FS; Li H
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7433-7441. PubMed ID: 32706083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender effect of hyperuricemia on the development of nonalcoholic fatty liver disease (NAFLD): A clinical analysis and mechanistic study.
    Xu K; Zhao X; Fu X; Xu K; Li Z; Miao L; Li Y; Cai Z; Qiao L; Bao J
    Biomed Pharmacother; 2019 Sep; 117():109158. PubMed ID: 31252266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining the role for uric acid in non-alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis: An opinion review.
    Brennan P; Clare K; George J; Dillon JF
    World J Gastroenterol; 2020 Apr; 26(15):1683-1690. PubMed ID: 32351286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma metabolomic profile in nonalcoholic fatty liver disease.
    Kalhan SC; Guo L; Edmison J; Dasarathy S; McCullough AJ; Hanson RW; Milburn M
    Metabolism; 2011 Mar; 60(3):404-13. PubMed ID: 20423748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomics profiling of steatosis progression in HepaRG
    Cuykx M; Claes L; Rodrigues RM; Vanhaecke T; Covaci A
    Toxicol Lett; 2018 Apr; 286():22-30. PubMed ID: 29355688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.